Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 12/2021

01-12-2021 | Original Article

Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma

Authors: Tao Fan, Yu Liu, Hengchang Liu, Liyu Wang, He Tian, Yujia Zheng, Bo Zheng, Liyan Xue, Fengwei Tan, Qi Xue, Shungeng Gao, Chunxiang Li, Jie He

Published in: Cancer Immunology, Immunotherapy | Issue 12/2021

Login to get access

Abstract

The clinical significance and comprehensive features of chemokines and their receptors in lung adenocarcinoma (LUAD) have not been clarified. We aimed to characterize the expression profiles of chemokine and chemokine receptor family members and construct a chemokine- and chemokine receptor-based prognosis signature. A total of 1511 patients with LUAD from seven independent cohorts were included in the study. The training set collected from The Cancer Genome Atlas (TCGA) database containing 468 cases. The validation was performed on the basis of six different cohorts downloaded from Gene Expression Omnibus (GEO) database. A five-chemokine- and chemokine receptor-(CXCL2, CXCL13, CCL26, CCL20, CX3CR1) based prognosis signature was constructed with TCGA dataset using LASSO Cox regression and Cox proportional hazards regression analysis. A multivariate analysis verified that this signature was an independent prognostic factor. The predictive value of this signature was further verified by other six independent cohorts and multiple clinical subtypes. We performed immune cell infiltration analysis and biological pathway analysis which provided more insight into this signature-related immune and inflammatory landscape and clarified the intrinsic molecular mechanism by which this signature could be used to predict clinical prognosis. Furthermore, we explored the close relationship between this signature and tumor mutation burden (TMB), neoantigen burden, PD-1, PD-L1, CTLA4, TIDE score, T cell-inflamed score. This signature provided a robust prognostic biomarker for LUAD and could serve as a predictor for immunotherapy response, which may be used as an important supplement to immunotherapy to achieve individualized tumor treatment by optimizing the prognostic management and immunotherapy for patients with LUAD.
Appendix
Available only for authorised users
Literature
10.
go back to reference Herbst R, Baas P, Kim D, Felip E, Pérez-Gracia J, Han J, Molina J, Kim J, Arvis C, Ahn M, Majem M, Fidler M, de Castro G, Garrido M, Lubiniecki G, Shentu Y, Im E, Dolled-Filhart M, Garon E (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England) 387(10027):1540–1550. https://doi.org/10.1016/s0140-6736(15)01281-7CrossRef Herbst R, Baas P, Kim D, Felip E, Pérez-Gracia J, Han J, Molina J, Kim J, Arvis C, Ahn M, Majem M, Fidler M, de Castro G, Garrido M, Lubiniecki G, Shentu Y, Im E, Dolled-Filhart M, Garon E (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England) 387(10027):1540–1550. https://​doi.​org/​10.​1016/​s0140-6736(15)01281-7CrossRef
12.
go back to reference Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West A, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez A, Grogan T, Mateus C, Tomasic G, Glaspy J, Emerson R, Robins H, Pierce R, Elashoff D, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571. https://doi.org/10.1038/nature13954CrossRefPubMedPubMedCentral Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West A, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez A, Grogan T, Mateus C, Tomasic G, Glaspy J, Emerson R, Robins H, Pierce R, Elashoff D, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571. https://​doi.​org/​10.​1038/​nature13954CrossRefPubMedPubMedCentral
15.
go back to reference Liao W, Overman M, Boutin A, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring D, Chang Q, Zhang J, Maru D, Maeda D, Zebala J, Kopetz S, Wang Y, DePinho R (2019) KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35(4):559-572.e557. https://doi.org/10.1016/j.ccell.2019.02.008CrossRefPubMedPubMedCentral Liao W, Overman M, Boutin A, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring D, Chang Q, Zhang J, Maru D, Maeda D, Zebala J, Kopetz S, Wang Y, DePinho R (2019) KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35(4):559-572.e557. https://​doi.​org/​10.​1016/​j.​ccell.​2019.​02.​008CrossRefPubMedPubMedCentral
17.
21.
go back to reference Green M, Chao N, Chhabra S, Corbet K, Gasparetto C, Horwitz A, Li Z, Venkata J, Long G, Mims A, Rizzieri D, Sarantopoulos S, Stuart R, Sung A, Sullivan K, Costa L, Horwitz M, Kang Y (2016) Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. J Hematol Oncol 9(1):71. https://doi.org/10.1186/s13045-016-0301-2CrossRefPubMedPubMedCentral Green M, Chao N, Chhabra S, Corbet K, Gasparetto C, Horwitz A, Li Z, Venkata J, Long G, Mims A, Rizzieri D, Sarantopoulos S, Stuart R, Sung A, Sullivan K, Costa L, Horwitz M, Kang Y (2016) Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. J Hematol Oncol 9(1):71. https://​doi.​org/​10.​1186/​s13045-016-0301-2CrossRefPubMedPubMedCentral
26.
30.
go back to reference Yang J, Gadgeel S, Sequist L, Wu C, Papadimitrakopoulou V, Su W, Fiore J, Saraf S, Raftopoulos H, Patnaik A (2019) Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J thoracic oncol official publicat Int Assoc Study Lung Cancer 14(3):553–559. https://doi.org/10.1016/j.jtho.2018.11.028CrossRef Yang J, Gadgeel S, Sequist L, Wu C, Papadimitrakopoulou V, Su W, Fiore J, Saraf S, Raftopoulos H, Patnaik A (2019) Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J thoracic oncol official publicat Int Assoc Study Lung Cancer 14(3):553–559. https://​doi.​org/​10.​1016/​j.​jtho.​2018.​11.​028CrossRef
31.
go back to reference Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res BCR 11(2):R15. https://doi.org/10.1186/bcr2234CrossRefPubMed Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res BCR 11(2):R15. https://​doi.​org/​10.​1186/​bcr2234CrossRefPubMed
34.
go back to reference Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung H, Kindler H, Lopez-Martin J, Miller W, Italiano A, Kao S, Piha-Paul S, Delord J, McWilliams R, Fabrizio D, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang Y (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21(10):1353–1365. https://doi.org/10.1016/s1470-2045(20)30445-9CrossRefPubMed Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung H, Kindler H, Lopez-Martin J, Miller W, Italiano A, Kao S, Piha-Paul S, Delord J, McWilliams R, Fabrizio D, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang Y (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21(10):1353–1365. https://​doi.​org/​10.​1016/​s1470-2045(20)30445-9CrossRefPubMed
35.
go back to reference Wang Z, Duan J, Cai S, Han M, Dong H, Zhao J, Zhu B, Wang S, Zhuo M, Sun J, Wang Q, Bai H, Han J, Tian Y, Lu J, Xu T, Zhao X, Wang G, Cao X, Li F, Wang D, Chen Y, Bai Y, Zhao J, Zhao Z, Zhang Y, Xiong L, He J, Gao S, Wang J (2019) Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol 5(5):696–702. https://doi.org/10.1001/jamaoncol.2018.7098CrossRefPubMedPubMedCentral Wang Z, Duan J, Cai S, Han M, Dong H, Zhao J, Zhu B, Wang S, Zhuo M, Sun J, Wang Q, Bai H, Han J, Tian Y, Lu J, Xu T, Zhao X, Wang G, Cao X, Li F, Wang D, Chen Y, Bai Y, Zhao J, Zhao Z, Zhang Y, Xiong L, He J, Gao S, Wang J (2019) Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol 5(5):696–702. https://​doi.​org/​10.​1001/​jamaoncol.​2018.​7098CrossRefPubMedPubMedCentral
37.
go back to reference Chae Y, Viveiros P, Lopes G, Sukhadia B, Sheikh M, Saravia D, Florou V, Sokol E, Frampton G, Chalmers Z, Ali S, Ross J, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin S, Oh M, Anker J, Park L, Wang V, Chuang J, Park W (2019) Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. J thoracic oncol offic publicat Int Assoc Study Lung Cancer 14(10):1807–1817. https://doi.org/10.1016/j.jtho.2019.06.016CrossRef Chae Y, Viveiros P, Lopes G, Sukhadia B, Sheikh M, Saravia D, Florou V, Sokol E, Frampton G, Chalmers Z, Ali S, Ross J, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin S, Oh M, Anker J, Park L, Wang V, Chuang J, Park W (2019) Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. J thoracic oncol offic publicat Int Assoc Study Lung Cancer 14(10):1807–1817. https://​doi.​org/​10.​1016/​j.​jtho.​2019.​06.​016CrossRef
38.
go back to reference Ott P, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad M, Hellmann M, Lin J, Friedlander T, Bushway M, Balogh K, Sciuto T, Kohler V, Turnbull S, Besada R, Curran R, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting Y, Dong J, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary L, Moles M, Manson K, Greshock J, Khondker Z, Fritsch E, Rooney M, DeMario M, Gaynor R, Srinivasan L (2020) A phase ib trial of personalized neoantigen therapy plus anti-pd-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183(2):347-362.e324. https://doi.org/10.1016/j.cell.2020.08.053CrossRefPubMed Ott P, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad M, Hellmann M, Lin J, Friedlander T, Bushway M, Balogh K, Sciuto T, Kohler V, Turnbull S, Besada R, Curran R, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting Y, Dong J, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary L, Moles M, Manson K, Greshock J, Khondker Z, Fritsch E, Rooney M, DeMario M, Gaynor R, Srinivasan L (2020) A phase ib trial of personalized neoantigen therapy plus anti-pd-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183(2):347-362.e324. https://​doi.​org/​10.​1016/​j.​cell.​2020.​08.​053CrossRefPubMed
39.
go back to reference Marshall LA, Marubayashi S, Jorapur A, Jacobson S, Zibinsky M, Robles O, Hu DX, Jackson JJ, Pookot D, Sanchez J, Brovarney M, Wadsworth A, Chian D, Wustrow D, Kassner PD, Cutler G, Wong B, Brockstedt DG, Talay O (2020) Tumors establish resistance to immunotherapy by regulating T-reg recruitment via CCR4. J Immunother Cancer 8(2):11. https://doi.org/10.1136/jitc-2020-000764CrossRef Marshall LA, Marubayashi S, Jorapur A, Jacobson S, Zibinsky M, Robles O, Hu DX, Jackson JJ, Pookot D, Sanchez J, Brovarney M, Wadsworth A, Chian D, Wustrow D, Kassner PD, Cutler G, Wong B, Brockstedt DG, Talay O (2020) Tumors establish resistance to immunotherapy by regulating T-reg recruitment via CCR4. J Immunother Cancer 8(2):11. https://​doi.​org/​10.​1136/​jitc-2020-000764CrossRef
46.
go back to reference Goswami S, Chen Y, Anandhan S, Szabo P, Basu S, Blando J, Liu W, Zhang J, Natarajan S, Xiong L, Guan B, Yadav S, Saci A, Allison J, Galsky M, Sharma P (2020) ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Translat Medicine. https://doi.org/10.1126/scitranslmed.abc4220CrossRef Goswami S, Chen Y, Anandhan S, Szabo P, Basu S, Blando J, Liu W, Zhang J, Natarajan S, Xiong L, Guan B, Yadav S, Saci A, Allison J, Galsky M, Sharma P (2020) ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Translat Medicine. https://​doi.​org/​10.​1126/​scitranslmed.​abc4220CrossRef
47.
go back to reference Hippe A, Braun S, Oláh P, Gerber P, Schorr A, Seeliger S, Holtz S, Jannasch K, Pivarcsi A, Buhren B, Schrumpf H, Kislat A, Bünemann E, Steinhoff M, Fischer J, Lira S, Boukamp P, Hevezi P, Stoecklein N, Hoffmann T, Alves F, Sleeman J, Bauer T, Klufa J, Amberg N, Sibilia M, Zlotnik A, Müller-Homey A, Homey B (2020) EGFR/Ras-induced CCL20 production modulates the tumour microenvironment. Br J Cancer 123(6):942–954. https://doi.org/10.1038/s41416-020-0943-2CrossRefPubMedPubMedCentral Hippe A, Braun S, Oláh P, Gerber P, Schorr A, Seeliger S, Holtz S, Jannasch K, Pivarcsi A, Buhren B, Schrumpf H, Kislat A, Bünemann E, Steinhoff M, Fischer J, Lira S, Boukamp P, Hevezi P, Stoecklein N, Hoffmann T, Alves F, Sleeman J, Bauer T, Klufa J, Amberg N, Sibilia M, Zlotnik A, Müller-Homey A, Homey B (2020) EGFR/Ras-induced CCL20 production modulates the tumour microenvironment. Br J Cancer 123(6):942–954. https://​doi.​org/​10.​1038/​s41416-020-0943-2CrossRefPubMedPubMedCentral
48.
go back to reference Gordy J, Luo K, Kapoor A, Kim E, Ayeh S, Karakousis P, Markham R (2020) Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-α and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model. Cancer immunol immunotherap CII 69(4):569–580. https://doi.org/10.1007/s00262-019-02471-0CrossRef Gordy J, Luo K, Kapoor A, Kim E, Ayeh S, Karakousis P, Markham R (2020) Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-α and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model. Cancer immunol immunotherap CII 69(4):569–580. https://​doi.​org/​10.​1007/​s00262-019-02471-0CrossRef
51.
go back to reference Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel S, Hida T, Kowalski D, Dols M, Cortinovis D, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera O, De Marinis F, Turna H, Lee J, Ballinger M, Kowanetz M, He P, Chen D, Sandler A, Gandara D (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (London, England) 389(10066):255–265. https://doi.org/10.1016/s0140-6736(16)32517-xCrossRef Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel S, Hida T, Kowalski D, Dols M, Cortinovis D, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera O, De Marinis F, Turna H, Lee J, Ballinger M, Kowanetz M, He P, Chen D, Sandler A, Gandara D (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (London, England) 389(10066):255–265. https://​doi.​org/​10.​1016/​s0140-6736(16)32517-xCrossRef
Metadata
Title
Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma
Authors
Tao Fan
Yu Liu
Hengchang Liu
Liyu Wang
He Tian
Yujia Zheng
Bo Zheng
Liyan Xue
Fengwei Tan
Qi Xue
Shungeng Gao
Chunxiang Li
Jie He
Publication date
01-12-2021
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 12/2021
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-021-02944-1

Other articles of this Issue 12/2021

Cancer Immunology, Immunotherapy 12/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine